Legal & General Group
SGMT icon

Legal & General Group’s Sagimet Biosciences SGMT Stock Holding History

Legal & General Group’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.1K Buy
+5,699
New +$38.8K ﹤0.01% 2807
2024
Q2 		– Sell
-2,147
Closed -$11.6K – 3499
2024
Q1 		$11.6K Buy
2,147
+1,660
+341% +$11.9K ﹤0.01% 3171
2023
Q4 		$2.64K Hold
487
– – ﹤0.01% 3355
2023
Q3 		$4.29K Buy
+487
New +$6.48K ﹤0.01% 3370

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Legal & General Group's SGMT Position: Q2 2026 in Review

Legal & General Group opened a new position in Sagimet Biosciences (SGMT) in Q2 2026: 5,699 shares worth $44.1K. The stake represents ﹤0.01% of the portfolio and ranks #2807 among its holdings. This is a return to the name: Legal & General Group previously reported a position in SGMT as recently as Q1 2024.

Legal & General Group first reported a position in SGMT in Q3 2023 and has held it in 4 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Legal & General Group held 5,699 shares of Sagimet Biosciences worth $44.1K as of Q2 2026.
  • Sagimet Biosciences was a new Legal & General Group position in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2807 holding.
  • Legal & General Group first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 4 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.